How do researchers and policy-makers decide on the value of health? Daniel Cressey looks at Britain's National Institute for Health and Clinical Excellence.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan
DARU Journal of Pharmaceutical Sciences Open Access 25 May 2013
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Thompson Coon, J. et al. Bevacizumab, Sorafenib tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation (Peninsula Technology Assessment Group, 2008).
Escudier, B. et al. Lancet 370, 2103-2111 (2007).
National Institute for Health and Clinical Excellence Final Appraisal Determination: Sunitinib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (NIH, 2009).
Additional information
See Editorial, see page 315 .
Related links
Rights and permissions
About this article
Cite this article
Cressey, D. Health economics: Life in the balance. Nature 461, 336–339 (2009). https://doi.org/10.1038/461336a
Published:
Issue Date:
DOI: https://doi.org/10.1038/461336a
This article is cited by
-
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan
DARU Journal of Pharmaceutical Sciences (2013)
